Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in advanced solid malignancies
NCT03568539Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jun 2018
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sintilimab in solid tumor and endometrial cancer (EC), sponsored by Innovent Biologics. Primary endpoint: Overall Response Rate (Confirmed) at 29 months. Started Jun 2018; status: completed.
02
Drugs
sintilimab
03
Conditions
solid tumorendometrial cancer (EC)
Beyond the preview
Go deeper on NCT03568539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568539.